Thermo Fisher Scientific Inc. said it is buying Brammer Bio for $1.7 billion in a move that would expand the lab-equipment company’s presence in the rapidly growing field of gene therapy. Closely held Brammer Bio, owned by private-equity firm Ampersand Capital Partners, provides pharmaceutical companies developing gene therapies and gene-modified cell therapies with outsourced research and drugmaking services. Gene...
Pharmaceutical research equipment manufacturer Thermo Fisher has expanded in the gene therapy space with its $ 500 acquisition of viral vaccine maker Brammer technologies from Ampersand Capital Partners . Thermo bio Marc Casper said official takeover talks began earlier this year and the two firms were already collaborating on some services . Thermo anticipates Brammer 's 2019 total revenue to be $ 250 m . The gene therapy product development and manufacturing market is currently worth $ 1bn and is growing at more than 25 % annually , Casper added .